Expression Screening of Fusion Partners from an E. coli Genome for Soluble Expression of Recombinant Proteins in a Cell-Free Protein Synthesis System by Ahn, Jin-Ho et al.
Expression Screening of Fusion Partners from an E. coli
Genome for Soluble Expression of Recombinant Proteins
in a Cell-Free Protein Synthesis System
Jin-Ho Ahn
1.¤a, Jung-Won Keum
2.¤b, Dong-Myung Kim
1*
1Department of Fine Chemical Engineering and Applied Chemistry, Chungnam National University, Daejeon, Republic of Korea, 2School of Chemical and Biological
Engineering, Seoul National University, Seoul, Republic of Korea
Abstract
While access to soluble recombinant proteins is essential for a number of proteome studies, preparation of purified
functional proteins is often limited by the protein solubility. In this study, potent solubility-enhancing fusion partners were
screened from the repertoire of endogenous E. coli proteins. Based on the presumed correlation between the intracellular
abundance and folding efficiency of proteins, PCR-amplified ORFs of a series of highly abundant E. coli proteins were fused
with aggregation-prone heterologous proteins and then directly expressed for quantitative estimation of the expression
efficiency of soluble translation products. Through two-step screening procedures involving the expression of 552 fusion
constructs targeted against a series of cytokine proteins, we were able to discover a number of endogenous E. coli proteins
that dramatically enhanced the soluble expression of the target proteins. This strategy of cell-free expression screening can
be extended to quantitative, global analysis of genomic resources for various purposes.
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Introduction
Rapid progress in sequencing technology is generating enor-
mous amounts of sequence data, making protein expression a
major bottleneck in the functional analysis of identified genetic
resources [1,2,3,4]. When compared to traditional cell-based gene
expression, cell-free protein synthesis offers excellent speed and
flexibility for parallel expression of multiple proteins [5,6,7]. For
instance, Kwon et al. were recently able to identify novel
transaminases from the genomic sequences of Rhodobacter sphaeroides
and Mesorhizobium loti strains by cloning-independent, cell-free
expression analysis of computer-predicted putative tranaminase
sequences [8]. In theory, cell-free synthesis enables functional
interpretation of protein-coding sequences from any genomes with
unsurpassed throughput.
However, similar to the case of cell-based gene expression, cell-
free synthesized proteins often fail to acquire a native soluble
structure, hampering downstream analysis of the translation
products. Combining target proteins with a solubility-enhancing
partner is one of the most generic, but effective tactics to promote
the solubility of recombinant proteins [9]. Many otherwise highly
insoluble proteins have been expressed as soluble fusion proteins
with a number of solubility-enhancing fusion partners including
glutathione-S-transferase (GST) [10]. maltose binding protein
(MBP) [11,12], thioredoxin (Trx) [13], NusA [14], and SUMO
protein [15], However, only a few established fusion partners are
currently available; thus, the development of novel fusion partners
is necessary to enable proficient expression and analysis of rapidly
increasing protein-coding sequences.
The useof fusion partners can influencethe translational efficiency
of the target genes as well as the solubility of the translation products.
Indeed, it is well known [16,17,18,19,20,21,22] that the nature of
initial codons next to the start codon has a crucial effect on the
expression efficiency of the downstream genes [23]. Therefore, both
theoverallexpressionlevelandrelativesolubilityofthetargetproteins
c a nb ea l t e r e du p o nN - t e r m i n a lf u s i o nw i t hf u s i o np a r t n e r s .S i n c e
neither the effect of the fusion partner sequences on the translation
efficiency or solubility of the translation product can be predicted,
selection of optimal fusion partners that allow the maximum
expression of soluble target proteins requires exhaustive expression
studies of different gene constructs. While combinatorial expression
analysis has been a challenging task due to the limited throughput of
cell-based gene expression, in this study, we conducted large scale
cell-free expression screening of solubility-enhancing fusion partners
from highly abundant E. coli proteins. Among the more than 1,000
different protein species that exist in E. coli cells during normal
growth, ribosomal proteins and other protein synthesis-related
proteins represent the most abundant protein species [24,25,26,27].
For example, ribosomal proteins account for as much as 34% of the
PLoS ONE | www.plosone.org 1 November 2011 | Volume 6 | Issue 11 | e26875total cellular protein mass and approximately 8% of the total cellular
volume of E. coli [26,28,29]. We speculated that these extremely
abundant proteins have more efficient folding pathways than other
endogenous proteins to enable tolerance of such a high concentration
inside the cells. Based on this assumption, it is expected that these
proteins could be used as the fusion partners to enhance the soluble
expression of heterologous proteins in a cell-free protein synthesis
system derived from E. coli extracts. During the initial screening, 88
fusion partner proteins were investigated for their ability to improve
the expression level and solubility of three model proteins (human b-
defensin 2, human epidermal growth factor, and human erythropoi-
etin). Among the 88 tentative fusion partners examined, 12 E. coli
proteins were found to be exceptionally effective at improving the
expression of model proteins in terms of the expression level and
solubility. The fusion partners selected during the primary screening
were then applied for soluble expression of 24 cytokines, a class of
proteins that are extremely difficult to express in soluble forms in the
present cell-free synthesis system derived from E. coli extract.
Through the expression screening analysis of 288 combinatorial
fusion constructs (12 fusion partners against 24 cytokines), we were
able to select potent fusion partners that enhanced the soluble
expression of target proteins by as much as 29 fold. Although the
effect of the examined fusion partners appeared to be protein specific,
a number of fusion partners led to particularly dramatic improve-
ments in the expression of soluble proteins.
Materials and Methods
Materials
ATP, GTP, UTP, CTP, creatine phosphate, creatine kinase and
E. coli total tRNA mixture were purchased from Roche Applied
Science (Indianapolis, IN). L-[U-
14C]leucine (11.9 GBq/mmol)
was obtained from Amersham Biosciences (Uppsala, Sweden).
E. coli strain BL21-Star
TM (DE3) was obtained from Invitrogen
(Carlsbad, CA). Oligonucleotides used in this study were
synthesized by Integrated DNA technologies on a 25 nmole scale
with standard desalting purification. All other reagents were
purchased from Sigma (St. Louis, MO) and used without further
purification. The S30 extract was prepared from strain BL21-
Star
TM (DE3) according to previously described methods [17,23].
cDNAs of human and murine cytokines were obtained from the
Bank for Cytokine Research (Chonbuk, Korea).
PCR construction of expression templates
Combinatorial gene constructs of fusion partners and target
proteins were prepared via three-step PCR as shown in Figure 1,
after which they were used directly as the expression templates without
purification. In the first-round PCR, fusion partner sequences from
the genomic DNA of E. coli K12 strain and target sequences from the
cloned genes were amplified separately. Pairs of fusion partners and
model protein genes were then joined and amplified in the subsequent
second and third-round PCR reactions, respectively (see Table S1 for
the sequences of the primers used in each PCR reaction).
Cell-free protein synthesis reactions
The standard reaction mixture for cell-free protein synthesis
consisted of the following components: 57 mM Hepes–KOH (pH
8.2), 1.2 mM ATP, 0.85 mM each of CTP, GTP, and UTP,
2 mM DTT, 0.17 mg/ml E. coli total tRNA mixture (from E. coli
strain MRE600), 0.64 mM cAMP, 90 mM potassium glutamate,
80 mM ammonium acetate, 12 mM magnesium acetate, 34 mg/
ml l–5-formyl-5,6,7,8-tetrahydrofolic acid (folinic acid), 1.0 mM
each of 20 amino acids, 2% polyethylene glycol (PEG) 8000,
67 mM creatine phosphate (CP), 3.2 mg/ml creatine kinase (CK),
0.01 mM L-[U-
14C]leucine (11.9 GBq/mmol, Amersham Biosci-
ences), and 10 mg/ml DNA, 24% (v/v) S30 extract.
The amounts of the cell-free synthesized proteins were
determined by measuring the TCA-precipitated radioactivity in
15 ml of reaction sample as previously described [30,31]. The
solubility of the synthesized protein was estimated based on the
ratio of the TCA-precipitated radioactivity of the reaction samples
before and after centrifugation at 20,000 RCF for 20 min [32].
Results
Preparation of combinatorial fusion constructs for cell-
free synthesis of aggregation-prone proteins
56ribosomalproteins,21translation-relatedfactorsandmolecular
chaperones,threeOB-folddomains,andeightofthemostcommonly
used fusionpartner proteins wereexamined as fusion partnersfor the
expression of aggregation-prone proteins (Table 1). For the initial
screening, each of the genes of the tentative fusion partners was fused
to the N-termini of three different model proteins, human b-defensin
2 (hBD-2), human epidermal growth factor (hEGF) and human
erythropoietin (hEPO). These model proteins were selected because
they show very poor expression levels and solubility in the present
cell-free protein synthesis system. The DNA constructs used to direct
the synthesis of fusion proteins were prepared through three-step
PCR procedures using six primers for each fusion construct as
outlined in Figure 1A. The constructs were designed to include the
T7 promoter and ribosomal binding site in the 59-UTR and the T7
terminator sequence inthe 39-UTR.In addition, the cleavage site for
Factor Xa (ATCGAAGGCCG, Ile-Glu-Gly-Arg) following a short
linker (GGTGGTAGT, Gly-Gly-Ser) was introduced between the
fusion partner and target protein coding genes (Figure 1B). After
being confirmed on an agarosegel for their size and relative amounts
(Figure 2), the PCR products coding for each fusion protein were
incubatedinthereactionmixtureforproteinsynthesisasdescribedin
the Materials and Methods.
Effect of fusion partners on the solubility and expression
level of target proteins
As shown in Figure 3, both the expression level and solubility of
the target proteins showed drastic variations in the presence of
different fusion partners (Tables S2, S3, S4). For example, in the
case of hBD-2 expression, the greatest increase in the amount of
translation product was obtained when the target gene was fused
with ibpA. However, in this case, most of the expressed protein
was found in the insoluble fraction. In contrast, fusion partners
such as S6 (30S ribosomal subunit S6) were found to enhance the
expression level while keeping most of the translation products
substantially soluble. Approximately 500 mg/ml of hBD-2 fusion
protein was produced, 56% of which was soluble when S6 was
fused with hBD-2. Furthermore, some of the examined fusion
partners, including L7 (50S ribosomal subunit L7) and fkpB, were
able to enhance the soluble expression of all three model proteins.
Based on molar quantities, when compared to the native protein,
the amount of soluble molecules was increased by approximately
19 – 32 fold.
Parallel screening of optimal fusion partners for soluble
expression of cytokine molecules
From the 88 tentative fusion partners examined above, we
selected 12 fusion partners that gave rise to more than a five-fold
increase in the amount of soluble products for at least two of the
three target proteins (Figure 4 and Figure S1). It should be
noted that only Trx was selected from the conventional fusion
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partners failed to improve the soluble expression of the primary
model proteins substantially. While some of the conventional
fusion partners greatly improved the solubility of the translation
product, the total yield of the fusion protein was not enhanced
as much (NTL9, Ub). In other cases, the partners did not
increase the solubility, while the overall yield was improved
(GST, NusA, Trx). In contrast, 11 fusion partners selected from
the E. coli genome were able to improve the efficiency of gene
expression while maintaining the translation product in a highly
soluble form.
We next evaluated the effect of the selected fusion partners
against 24 different cytokine species derived from humans and
mice. When expressed from their native sequence, most of the
examined cytokines exhibited very low yield and poor solubility
(139 mg/ml and 18% average yield and solubility, respectively).
However, upon fusion with the 12 selected fusion partners, most
of the examined cytokines showed a substantially enhanced yield
of soluble products due to increases in both total protein
production and solubility (Figure 4). Among those, L7 and S6
were found to be exceptionally effective at enhancing the
production of soluble proteins. Soluble yields of 20 out of 24
examined cytokines were improved when fused with the L7
protein with levels of enhancement ranging from 1.5 to 29 fold.
Similarly, S6 increased the soluble expression of 21 cytokines
from 2.5 to 15 fold.
Figure 1. Three-step PCR reactions to assemble linear expression template. (A) Schematic representation of PCR-based generation of fusion
constructs. Two primary PCR products with defined overlapping ends are synthesized by the first PCR reaction. These two fragments are joined in a
second PCR, overlap extension PCR and subsequent third PCR step introduces the regulatory elements necessary for transcription and translation to
the fused target genes. (B) Sequence elements of final amplified expression template.
doi:10.1371/journal.pone.0026875.g001
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properties of protein
The level of enhancement in the solubility and expression in
response to fusion with the 12 fusion partners showed wide
distributions depending on the targeted cytokine molecules. The
set of expression and solubility data generated in this study
(12624=288) was analyzed for the presence of common
properties of the nucleotide and amino acid sequences that
determine the expression efficiency and solubility of the
expressed fusion molecules. First, total expression levels of the
examined constructs did not show clear correlations with their
GC contents (Figure 5A). However, there appeared to be a
positive correlation between protein expression efficiency and
codon adaption index (CAI) (Figure 5B) as well as a certain degree
of bias in the initial nucleotide sequence of the well-expressed
fusion constructs (Figure 5C). Since all of the fusion partners
were added at the N-terminus of the target proteins, this finding
reflects the relative expression efficiency of the fusion partners
due to the identities of their initial codons. The solubility data
generated from the primary and secondary screening procedures
were also analyzed to explore the general pattern correlating the
physicochemical properties of the fusion proteins and their
solubility. While the solubility of the fusion molecules appeared
to be related to the composition of amino acids (for example, the
contents of charged amino acids), the distribution of solubility
generally seemed to occur at random against different param-
eters (Figure 5 D–G). Therefore, the effect of fusion partner
appears to be due to the intrinsic nature of the fusion partners,
rather than changes in the amino acid composition introduced
by the fusion partners.
Figure 2. Agarose gel electrophoresis of PCR products.
doi:10.1371/journal.pone.0026875.g002
Table 1. Fusion partners used in this study.
Category Partner protein
Conventional fusion partner (8) MBP[36], Trx[37], GST[38], NusA[39], Ubiquitin (Ub)[40], Domain I of IF-2 (DI-IF2, 1–158)[41], N-terminal domain of L9
(NTL9, 1–56) [42]
Ribosomal protein (56) 30S ribosomal subunit
S1, S2, S3, S4, S5, S6, S7, S8, S9, S10, S11, S12, S13, S14, S15, S16, S17, S18, S19, S20, S21, S22
50S ribosomal subunit
L1, L2, L3, L4, L5, L6, L7, L9, L10, L11, L13, L14, L15, L16, L17, L18, L19, L20, L21, L22, L23, L24, L25, L27, L28, L29, L30, L31,
L31B, L32, L33, L34, L35, L36
Translation-related factor (4) EF-Tu, EF-P, IF1, IF3
Chaperone protein (17) IbpA, IbpB, Skp, SlyD, DsbA, DsbB, DsbC, SecB, SecE, SecG, GrpE, FkpB, FklB, GroEL, GroES, GroEL191–345, GroEL191–376
OB-fold domain (3)* LysN1–145, AspN1–102, AsnN1–99
*This family contains OB-fold domains that bind to nucleic acids (oligonucleotide/oligosaccharide-binding fold). The family includes the anti-codon binding domain of
lysyl, aspartyl, and asparaginyl-tRNA synthetases [43].
doi:10.1371/journal.pone.0026875.t001
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three different genes (hBD2, hEGF, hEPO) using three-step PCR. All PCR products coding each fused gene were directly used as expression templates
for cell-free protein synthesis where expression efficiency and solubility were measured. After 3 h for cell-free expression, the reaction samples were
centrifuged at 10,000 rpm for 30 min. Both pellet and soluble fractions were analyzed by radioactivity counting. The degree of solubility and
expression yield enhancement for each fusion gene is colorized with red and blue respectively.
doi:10.1371/journal.pone.0026875.g003
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While the proteomics approach for understanding the networks
of protein function is represented by characterization of global
changes at the level of their expression/post-translation modifica-
tion by mass spectrometry and 2D gel electrophoresis, data
obtained from proteomic analysis frequently needs to be
complemented with detailed information regarding the individual
proteins participating in the functional networks, which can be
accelerated using a reliable method for high-throughput expres-
sion and analysis of protein molecules. By programming with
PCR-amplified genes, cell-free protein synthesis enables multi-
plexed, rapid preparation of protein molecules for subsequent
downstream analyses such as structure determination and analysis
of biological activities. With the use of automated liquid handling
devices, thousands of recombinant proteins can be readily
prepared for genome-wide expression analysis of ORFs, providing
an ideal platform for ‘reverse proteomics’. In addition, unlike cell-
based gene expression, the amounts of cell-free synthesized
proteins can be precisely determined by measuring the incorpo-
ration of labeled amino acids into the synthesized proteins,
allowing for precise quantification of total and soluble translation
products.
However, the solubility issue of the expressed proteins remains
the major hurdle to overcome for large-scale investigation of
protein function. In this study, cell-free expression analysis of
combinatorial fusion constructs between aggregation-prone target
proteins and a series of fusion partners was used in an attempt to
Figure 4. Combinatorial examination of fusion partners for the expression of different cytokines. (A) Fold enhancement of soluble
expression of cytokines by the examined fusion partners. (B) Fold enhancement of total expression yield by fusion with the examined fusion partners.
(C) A bubble chart where the size of each bubble diameter is proportional to the fold enhancement of the expression efficiency of total protein.
Detailed stacked bar graphs of individual fusion protein are shown in Figure S1.
doi:10.1371/journal.pone.0026875.g004
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expression level of soluble proteins. In addition to the commonly
used generic fusion partners, we included highly abundant E. coli
proteins in the list of tentative fusion partners. This was done for
two reasons. First, although the primary purpose of adding fusion
partners is to improve the solubility of target proteins, the presence
of a fusion partner can also influence the efficiency of the
expression of the entire fusion protein due to the initial codon
effect. Therefore, by using the sequences of proteins that are highly
expressed by the E. coli translational machinery, we expected to
enhance the overall expression level of the target proteins in our
cell-free synthesis system derived from E. coli. In addition, we
assumed that highly abundant proteins have properties that
enables them to decrease their aggregation, which will be
necessary for bacterial cytoplasmic proteins to minimize their
deposition at the concentrations required for their proper
biological functions [33,34]. Therefore, by using those abundant
proteins as the fusion partners, we sought to enhance both the
expression level and solubility of the resulting fusion proteins.
Cytokines were selected as the target proteins since they are a
Figure 5. Statistical analysis for the relationships between solubility/yield and physicochemical properties. (A) Relationship between
expression efficiency and GC content. (B) Histograms of codon adaptation index for highly expressed genes and poorly expressed genes. (C)
Sequence logos of downstream region of proteins with high expression efficiency (.70% enhancement), which was created with WebLogo software
[44]. (D) Solubility distribution for quantified proteins. Histogram of solubility for the quantified proteins in Figure 3. The proteins with solubilities
,30% and .70% were defined as the aggregation-prone (Agg, colored blue) and soluble (Sol, colored pink) groups, respectively. Scatter plot of
solubility versus isoelectric point (E) and molecular weight (F). Histograms of the relative contents of negatively charged residues (Asp and Glu) (Left),
hydrophobic residues (Val, Leu and Ile), aromatic residues (Phe, Tyr, and Trp), and positively charged residues (Lys, Arg, and His) in the Total, Agg, and
Sol groups.
doi:10.1371/journal.pone.0026875.g005
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communication and thus have great potential for use as potential
therapeutics as well as drug targets.
As expected, the E. coli proteins selected based on their
abundance level were able to increase the soluble expression of
the targeted cytokine proteins as well as the model proteins for
primary screening. In this study, when several hundred fusion
genes were systematically examined in parallel, different fusion
partner proteins showed increased expression of soluble target
proteins as well as the overall yield of expressed protein, with
increases of as much as 29 fold and 15 fold, respectively, being
observed in response to their fusion with aggregation-prone
proteins. To understand the correlation between the sequence
information and the expression efficiency/solubility in our fusion
protein expression result, statistical analysis of fusion constructs
was conducted. The results showed that AT nucleotides are biased
in the initial region of highly expressed fusion genes. However, no
significant correlation between physicochemical properties and the
solubility of fused genes was observed. We also attempted to draw
a common pattern of sequence-solubility relationship of the
expressed fusion proteins using a computational sequence analysis
algorithm (Table S5). However, again, we were not able to find
meaningful correlations between the sequence properties obtained
from the AGGRESCAN analysis and experimental results of
protein solubility [35]. This might result from the difference
between in vivo and in vitro environments for protein synthesis,
which needs further investigation in the future.
Since the protein solubility varies significantly depending on the
specific combination of fusion partner and target proteins, effective
fusion partners for a given target protein should be determined
empirically, which demands a high-throughput strategy for a
large-scale gene fusion and protein expression system of fused gene
constructs.
While the present study focused on the cell-free expression of
aggregation prone proteins, we expect that the results presented
herein can be extended to cell-based protein expression for large
scale production of specific target proteins since the present cell-
free protein synthesis system mimics the cytoplasmic conditions of
the E. coli cells. Since most of the fusion partners screened in this
study are ribosomal subunit proteins, the possibility that their use
in cell-based gene expression can interfere with the assembly of
endogenous ribosomes cannot be excluded; nevertheless, they
could be engineered to be incapable of participating in ribosome
assembly. Furthermore, the approach presented herein will be
applicable to various fields involving global expression and analysis
of various genomic resources.
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Figure S1 Expression yield and solubility of cytokines fused with
12 fusion partners. 24 cytokine genes that otherwise exhibit poor
expression level and solubility were fused by PCR with 12 fusion
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